Command Palette

Search for a command to run...

Discover

Supreme Court Blocks Restrictions, Preserves Nationwide Mail Access to Mifepristone

Supreme Court Blocks Restrictions, Preserves Nationwide Mail Access to Mifepristone
View gallery

The Supreme Court on Thursday temporarily preserved nationwide access to the abortion pill mifepristone by mail and telehealth, blocking a lower-court order that would have forced patients to obtain the drug in person while a Louisiana-led lawsuit proceeds through the courts. The unsigned order means mifepristone, used in roughly two‑thirds of U.S. abortions, will remain available via pharmacies, telehealth and mail delivery for at least several more months as appeals continue. theguardian +1

The dispute arose after the U.S. Court of Appeals for the Fifth Circuit ruled on May 1 that the Food and Drug Administration’s 2023 decision to allow pharmacy dispensing and mail-order prescriptions likely violated federal law, and reinstated an in‑person pickup requirement nationwide. Drugmakers Danco Laboratories and GenBioPro asked the justices to step in, warning that the Fifth Circuit’s order would abruptly cut off mail access for patients and destabilize the FDA’s framework for medication abortion. theguardian +2

A Procedural Ruling With High Stakes for FDA Power

By granting the manufacturers’ emergency request, the Court did not decide who is right about mifepristone’s regulation; instead, it froze the Fifth Circuit’s restrictions while the justices consider whether to take the case on the merits later this term or next. The order leaves in place the FDA’s 2023 rules, which removed an in‑person dispensing requirement and allowed certified pharmacies to ship the pills after telehealth consultations. usnews +1

Louisiana and allied states have argued that the FDA violated the Administrative Procedure Act when it relaxed mifepristone rules and that the 19th‑century Comstock Act bars mailing abortion drugs altogether. They say those policies burden state abortion bans and impose costs on state Medicaid programs. Federal officials and drugmakers countered that the states lack standing and that letting a single appeals court effectively rewrite national drug-safety conditions would invite similar attacks on other FDA‑approved medications. Former FDA leaders and major pharmaceutical companies echoed that concern in friend‑of‑the‑court briefs, warning that judicial second‑guessing of risk‑management decisions could reverberate across the drug market. afslaw +2

What the Decision Means for Abortion Access on the Ground

For patients, the ruling keeps the status quo in place: people in states where abortion remains legal can continue to obtain mifepristone from brick‑and‑mortar pharmacies, through telehealth providers, and by mail. That pathway has become central to post‑Dobbs abortion care, especially for those in rural areas or in states with few clinics; telehealth now accounts for roughly one quarter of medication-abortion encounters, and more than half of telehealth abortions in mid‑2025 went to people living in states with bans or telemedicine restrictions. reuters +1

Advocates for abortion rights called the order a crucial but fragile reprieve, stressing that medication abortion — typically a regimen of mifepristone followed by misoprostol — now accounts for about 63% of abortions nationwide. Opponents, including Justices Clarence Thomas and Samuel Alito in separate dissents, argued the Court was too quick to shield drugmakers and the FDA, framing the case as a test of whether states can enforce their own abortion restrictions against a permissive federal regulatory regime. nbcnews +2

Looking Ahead

The Court’s emergency order signaled that a majority was not willing, at least for now, to let a regional appeals court rapidly reshape nationwide access to a widely used, long‑approved drug. But the underlying questions — how far states can go in challenging FDA decisions, whether the Comstock Act can be revived to police abortion medications, and how courts should treat telehealth abortion that crosses state lines — remain unresolved. When the justices eventually take up Louisiana v. FDA in full, their ruling is poised to redefine not only the future of medication abortion, but also the balance of power between states, federal regulators and the courts in setting national drug policy. theguardian +2